Please assess the completion status of the following clinical trial:

Trial Title: Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Infants will be eligible for the DANCE trial if they have a gestational age \> 36 weeks by best obstetric estimate, are \< 12 hours old and have evidence of moderate-severe acute perinatal HIE. Eligibility will also include criteria presently used in the NICU to initiate hypothermia:~1. \< 6 hours after birth~2. History of an acute perinatal event (abruption, cord prolapsed, severe fetal heart rate abnormality)~3. Severe fetal or early (\< 1 hour age) neonatal acidosis: arterial pH ≤ 7.0 or a base deficit ≥ 16m mEq/ L~4. If a blood gas is not available or a blood gas at \<1 hour of age has a pH between 7.01 and 7.15, or a base deficit is between 10 and 15.9 mEq/L, additional criteria will be required:~   * acute perinatal event AND~  * either a 10-min Apgar score ≤ 5 or assisted ventilation initiated at birth and continued for at least 10 minutes.~Exclusion Criteria:~1. Major congenital and/or chromosomal abnormalities~2. Prenatal diagnosis of brain abnormality or hydrocephalus~3. Severe growth restriction (\< 1800g)~4. Central venous hematocrit \> 65%, platelet count \> 600,000/dL, and/or neutropenia (ANC \< 500 µL)~5. Maternal history of major vascular thrombosis or multiple fetal losses (\> 3 spontaneous abortions)~6. ECMO~7. Infant judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- High dose Darbepoetin alfa (Type: ACTIVE_COMPARATOR): 10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
- Low dose Darbepoetin alfa (Type: ACTIVE_COMPARATOR): 2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old

Based on this trial design, predict the completion outcome and termination type (if applicable).